Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ladiratuzumab vedotin - Merck/Seagen

Drug Profile

Ladiratuzumab vedotin - Merck/Seagen

Alternative Names: MK-6440; SGN-LIV1A

Latest Information Update: 15 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Seattle Genetics
  • Developer Merck & Co; Quantum Leap Healthcare Collaborative; Seagen
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Adenocarcinoma; Breast cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Small cell lung cancer

Most Recent Events

  • 14 Dec 2023 Seagen has been acquired by Pfizer
  • 28 Nov 2023 Seagen terminates a phase II trial in Oesophageal cancer, Malignant melanoma, Non-small cell lung cancer, Small cell lung cancer, Head and neck cancer, Adenocarcinoma and Prostate cancer (Inoperable/Unresectable, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA, Taiwan, United Kingdom, South Korea, Australia, Italy (IV) due to portfolio prioritization(NCT04032704)
  • 04 Feb 2023 Seagen completes a phase-I development in Breast-cancer (Metastatic disease, Combination therapy, Monotherapy, Second-line therapy or greater, Late-stage disease, Inoperable/unresectable) in USA (IV, Infusion) (NCT01969643)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top